TSC1 and tuberous sclerosis: Given that the pathogenesis of TSC is related to the loss of the negative regulatory function of the TSC1/TSC2 complex on the mTOR pathway, mTOR inhibitors are considered ideal targeted drugs for the treatment of TSC.